Patients with multiple sclerosis (MS) typically present with a clinically isolated syndrome (CIS), which eventually develops into relapsingremitting MS (RRMS); after a varying number of years, most patients transform into secondary progressive MS (SPMS). An alternative course is primary progressive MS (PPMS), which develops more rapidly from onset and is also inevitably accompanied by some decline in walking ability.
although less perceptibly, in the early stages of the disease, including in patients with CIS. Since the onset of MS occurs most often between 20 and 30 years of age, when individuals are likely to be otherwise fit and leading productive lives, the loss of mobility has a more severe impact than it might if it were to develop in older persons already living a more sedate lifestyle.
9-11 As discussed above, age at onset of MS affects prognosis: in younger patients the disease generally progresses more slowly, but also leads to greater disability than does onset later in life.
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Despite the long-established recognition of mobility impairments in MS, the ability to walk is generally not sufficiently nor specifically assessed by therapists or physicians, and quantitative measures are frequently not used to determine and continuously monitor the impact of this disability on patients and their care-givers. This review aims to identify the impact of decreased walking ability on patients'
lives. An accompanying article in this issue considers the various methods used to assess both general disability and specific aspects of walking ability in MS (see pages 61-8).
Impaired Mobility Limits Activities and Social Participation -An Important Part of the Burden and Impact of Multiple Sclerosis
As noted above, MS often leads to significantly impaired abilities.
Recently, the International Classification of Functioning (ICF)
produced by the World Health Organization (WHO) proposed terms related to disability and handicap that aim to avoid negative connotations. What used to be called 'disability' is now described as 'activities', and instead of 'handicap' the emphasis is on 'participation in social life'. Core sets of terms related to MS were developed by the ICF at an International Consensus Conference following established rules. In some current and older publications, however, the former terms disability and handicap are used, and when referring to literature this article has retained the reported terminology.
The general decrease in levels of activities and social participation that accompanies the progression of MS pathology, the loss of walking ability in particular, gradually reduces a patient's functional capacity -both in employment and in his or her private and social life. Data from studies over the past two decades show that after disease onset, the median time until a patient has some limitation in walking ability is eight years, the median time until the patient needs some support, such as a walking stick, is 20 years and the median time until the patient is confined to a wheelchair is 30 years. with long-duration MS rated walking to be the most important (see Figure 2) . Surprisingly, this was greater than the numbers rating visual function (16 and 24%), thinking and memory (8 and 15%) or even lack of pain (11 and 9%) as their most important domains. On the basis of these findings, it was concluded that patient-centred scales, tailored to the value of these abilities, should be major outcome criteria for the assessment of any therapies in MS.
Further work highlighting the importance of walking included the Table  1 ). The magnitude of this burden was concluded to be severe relative to the general population.
The effects of MS symptoms, impact on QoL, costs and burden of disease were analysed in a recent literature search of clinical studies published up to January 2009. 16 Results from the identified clinical studies showed that impaired mobility was considered to be of high concern among many patients. For example, in one chosen study, a postal survey of 1,992 patients with MS in the UK, >90% of patients reported mobility as a concern and pain was reported by >80% of patients; among patients receiving disease-modifying treatments (DMTs), only 52% reported improvement in mobility. 16, 17 In another study, spasticity was reported to affect the life of 44% of patients.
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The authors of the review concluded that there is a need for greater recognition of disability and its effects in MS as well as a need for targeted treatments for specific impairments to improve QoL and reduce indirect costs. 16 Another literature search covering the period 1980-2008 found that, across a number of studies, the prevalence of impaired mobility ranged from 50 to >90%. 15 This variability was attributed to differences in the methods employed, definitions used and patient populations included in the studies reviewed. Impaired mobility was also shown to be associated with reductions in QoL and activities of daily living and productivity, and was regarded as a concern for loss of independence. These findings highlighted the need for more comprehensive and consistent assessments of walking impairment and further evaluation from a patient's perspective. MS patients, 41% of responders needed assistance in walking, including 12% who required a wheelchair and 17% who needed support when crossing a room. 19 Among patients with walking difficulties, 58% reported that this difficulty had caused them to miss major personal events (vacations, weddings, birthdays, etc.), 74%
said that their walking difficulty had increased household responsibilities among family members and 70% agreed that this was the most challenging aspect of their disease. Respondents who had walking difficulty and were also employed (n=131) reported a substantial impact on work. Among these, 79% reported that walking difficulty had a negative impact on their employment, and this was a result of specific needs such as taking time off (44%), reducing working hours (34%) or switching careers (31%) (see Figure 3) .
The impact of MS-associated walking impairment on care-givers has also been investigated. A study of 445 patients with clinically definite MS and their care-givers (n=445) conducted in Italy examined QoL in
Multiple Sclerosis 
A notable investigation of the socioeconomic effect of MS is the North
American Research Consortium on Multiple Sclerosis (NARCOMS). This is a self-reported registry of persons with MS who are assessed twice yearly using both paper and web-based questionnaires. 21 The study assesses the effect of mobility performance, scored on a six-point scale (0 = no disability to 6 = total disability), on aspects of life. A recent analysis of 8,180 persons with MS in this registry showed that, in both men and women, employment decreased significantly with decreasing mobility performance (p<0.0001 for both sexes) (see Figure 4) .
Interestingly, this association was significant even at low mobility scores of 0, 1 and 2 (mild gait disability; p<0.0001 for all). Furthermore, for the total cohort, paid income was significantly correlated with mobility (p<0.0001). The greatest reductions in all income measures occurred at the lowest level of mobility impairment (0 to 1; minimal gait disability), suggesting that small decreases in walking ability have a severe effect on employment capability. Reductions in income levelled off at higher mobility scores. The authors suggested that this showed that many persons with MS cease employment during early stages of the disease when they have less severe mobility impairment.
21
The impact of MS on employment had already been demonstrated in an older study of 602 persons with MS (430 women and 172 men) conducted at neurological treatment centres across Canada.
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In total, 66% of the participants were unemployed and 78% of these believed their unemployment was related to MS symptoms.
The most frequent patient-reported MS-related reasons for unemployment were walking difficulties (41%), fatigue (39%) and In one report, the effects of MS on two separate married couples were considered and showed an increasing awareness of change in abilities over time. 23 In one of the couples, a woman 53 years of age who had been diagnosed with SPMS 20 years earlier stated that during the course of the disease her "horizons had shrunk". She needed a walker and was increasingly dependent on her husband for everyday functions. Prior to MS onset, she had enjoyed activities such as walking, rock climbing and swimming. When she had been forced to stop these activities due to her MS, her lifestyle had been severely curtailed. Six years previously she could manage to walk four blocks, but now she could only manage two and that would take 40 minutes. Another couple told a similar story. The husband, who was 71 years of age, had been diagnosed with MS 38 years earlier and had been confined to a wheelchair for 20 years. He and his wife, who was his care-giver, had previously enjoyed dancing and family activities, but these had gradually stopped due to his progressive MS. On one occasion while alone in the house, the man had slipped from his wheelchair and had to crawl on his elbows and stomach down his hallway to reach the telephone to get help; it had taken him two hours to cover the short distance. Both couples reported declining social activity and increasing isolation, largely resulting from decreased walking ability and mobility.
The value of improved monitoring and support in MS patient mobility is also illustrated in a report of a 40-year-old man who had a 10-year history of MS. 24 He increasingly relied on a wheelchair for mobility, but was too weak to propel it outdoors. He had decreasing levels of endurance and this severely restricted his walking ability. He was concerned about his inability to go outside and was becoming isolated. He was hospitalised with ataxia and increasing tremors that resulted from his efforts to move about. In the hospital, his mobility needs were assessed and a treatment plan was formulated. He was 
Future Developments in Mobility Assessment and Management in Multiple Sclerosis
In the coming years, the importance of impaired mobility in MS will be increasingly recognised and is likely to be monitored more closely by neurologists. Currently, data assessing the impact of mobility impairment in MS are limited both in scope and in the numbers of patients involved. As a consequence, walking ability, which is the most significant aspect of overall mobility, is an insufficiently monitored aspect of the impact of MS. In fact, as in many other diseases, we are only just beginning to recognise the difference between what patients and clinicians consider important.
Studies in larger populations of MS patients using general purpose and more specific methods for assessing mobility will contribute to a better understanding of the clinical meaningfulness of mobility data in MS. Data from these studies are likely to result in recommendations and guidelines that specify this faculty be more accurately assessed as part of both the diagnostic process and continuous monitoring throughout the disease course.
Awareness of walking and mobility impairment as a particularly serious consequence of MS, in terms of its contribution to decreased capacity for employment and normal day-to-day functioning, is likely to increase among neurologists, general physicians, patients and care-givers. Demand for more intensive mobility assessment may therefore increase, and continued monitoring throughout the course of MS may allow findings to be used to better assess patient needs.
Increasing recognition of impaired mobility by physicians as a major factor in MS will drive interventions to address patients' needs and significantly improve many aspects of patients' lives. It 
